6-Sulfatoxymelatonin predicts treatment response to fluoxetine in major depressive disorder

Freitas, Juliana Jury; Xavier, Nicóli Bertuol; Tonon, André Comiran; Carissimi, Alícia; Pizutti, Leandro Timm; Ilgenfritz, Carlos Augusto Vieira; Markus, Regina Pekelmann; Hidalgo, María Paz Loayza

doi:10.1177/2045125319881927

Cited by 4 publications

(1 citation statement)

References 25 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results emphasize the use of melatonin as clinical biomarker and as a potential marker of treatment response. Moreover, 6-sulfatoxymelatonin, the main urinary melatonin metabolite, has been proposed as a biomarker for several antidepressant treatments [17,18]. On the other hand, patients diagnosed with major depressive disorder (MDD) show significantly higher waking salivary cortisol levels compared to healthy subjects [19].…”

Section: Introductionmentioning

confidence: 99%

Antidepressants and Circadian Rhythm: Exploring Their Bidirectional Interaction for the Treatment of Depression

2021

View full text Add to dashboard Cite

Scientific evidence that circadian rhythms affect pharmacokinetics and pharmacodynamics has highlighted the importance of drug dosing-time. Circadian oscillations alter drug absorption, distribution, metabolism, and excretion (ADME) as well as intracellular signaling systems, target molecules (e.g., receptors, transporters, and enzymes), and gene transcription. Although several antidepressant drugs are clinically available, less than 50% of depressed patients respond to first-line pharmacological treatments. Chronotherapeutic approaches to enhance the effectiveness of antidepressants are not completely known. Even so, experimental results found until this day suggest a positive influence of drug dosing-time on the efficacy of depression therapy. On the other hand, antidepressants have also demonstrated to modulate circadian rhythmicity and sleep–wake cycles. This review aims to evidence the potential of chronotherapy to improve the efficacy and/or safety of antidepressants. It includes pre-clinical and clinical studies that demonstrate the relevance of determining the most appropriate time of administration for antidepressant drugs. In parallel, their positive influence on the resynchronization of disrupted circadian rhythms is also herein discussed. It is expected that this review will promote the investigation of chronotherapy for the treatment of depression, contribute to a better understanding of the relationship between antidepressants and circadian rhythms, and consequently promote the development of new therapeutics.

show abstract

Section: Introductionmentioning

confidence: 99%